Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. N. Srivastava, S. K. Agarwal, S. Anupurva, S. Subramanian, R. R. Purryag (Varanasi (Uttar Pradesh), India). Drug resistant pattern of antitubercular drugs in India. Eur Respir J 2008; 32: Suppl. 52, 2542

Member's Comments

No comment yet.

Related content which might interest you: Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006 Anti-tuberculosis drugs Source: International Congress 2017 – State of the art session: "Respiratory infections" Year: 2017 Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Drug resistant TB treatment outcomes in Novokuznetsk Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control Year: 2007 Availability of anti-tuberculosis drugs in Europe Source: Eur Respir J 2012; 40: 500-503 Year: 2012 Cardiotoxicity of a complex of anti-tuberculosis drugs with the inclusion of fluoroquinolones and bedaquiline in an experiment on rats Source: Virtual Congress 2021 – Immunological and molecular characterisation of tuberculosis disease and infection Year: 2021 Increasing anti-tuberculosis drug resistance in the UK Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013 Pre-chemotherapy drug sensitivity test for antitubercular drugs in India – is it essential? Source: Eur Respir J 2005; 26: Suppl. 49, 649s Year: 2005 Drug resistance in Bulgaria Source: Eur Respir J 2001; 18: Suppl. 33, 471s Year: 2001 Drug resistant tuberculosis in Belarus Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003 Drug resistant tuberculosis at a drug resistant tuberculosis centre, India- Analysis of outcome Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 Frequency of resistance to antituberculosis drugs in 2003 year Source: Eur Respir J 2004; 24: Suppl. 48, 654s Year: 2004 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 A Cuban successful history on antituberculosis treatment and drug resistance surveillance Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 Resistance to second-line antituberculous drugs of Mtb strains in TB institute clinic Source: Eur Respir J 2007; 30: Suppl. 51, 442s Year: 2007